Article

Phlorotannin-incorporated mesenchymal stem cells and their promising role in osteogenesis imperfecta

Iranian Journal of Medical Hypotheses and Ideas 07/2012; 6(2):85–89. DOI: 10.1016/j.jmhi.2012.09.002

ABSTRACT Osteogenesis imperfecta as the name suggests, is a bone disorder characterised by imperfect bone mineralisation and development. The key defect lies in the osteoblast–osteoid cycle, leading to insufficient calcification and consequently weak bones. Osteogenesis imperfecta patients are prone to fractures. Till date, numerous growth hormone/synthetic analogues have been used therapeutically in osteogenesis imperfecta patients and they do provide temporary relief, but not without numerous unwanted side effects. The intervention offered by such treatments is mainly at the symptomatic level, with temporary pain relief and some degree of mineralisation of available osteoids; but the root cause of the disease remains unattended. Such treatment modalities fail to promote mesenchymal stem cell osteogenic differentiation and tackle the fundamental deficiency of osteoids. This paper suggests a unique and hitherto unimplemented approach for treatment of osteogenesis imperfecta at the cellular level through application of a natural source, ‘Brown algae isolated phlorotannins’, which promote mesenchymal stem cell differentiation by increasing alkaline phosphatase activity, calcific mineralisation and total protein and collagen synthesis. This natural extract, when integrated directly with mesenchymal stem cells, will boost cellular differentiation into healthy bone-forming cells. The modality will strengthen the bone intrinsically and without the adverse reactions of routine pharmacotherapeutic agents.

0 Bookmarks
 · 
44 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Over the past half-century, biomaterials have been used in orthopaedic surgery world widely, but orthopaedic implant-associated infections (OIAIs) are still a puzzle for orthopaedic surgeons, which may result in prolonged hospitalisation, poor functional status and high costs. The presence of implants increases the risk of microbial infection; moreover, the formation of bacterial biofilm leads to a higher resistance to antibiotics and local immune response. In such cases, conventional systemic delivery of drugs seems to be fairly inefficient and out-dated. Owing to this, debridement and/or removing the implant always become the only solution. Hence, it needs a simple, minimally invasive and effective therapy to eradicate the problem. There are abundant evidences showing that extracorporeal shock wave therapy (ESWT) has favourable effects on stimulating callus formation, inducing angiogenesis, promoting osteogenesis and relieving pain. Studies also indicated that ESWs have a significant bactericidal effect on bacterial strains of bone- and implant-associated infections. Therefore, a hypothesis proposed herein is that ESWT may well be an effective adjuvant treatment for OIAI by controlling infection, inducing bone regeneration and promoting re-osseointegration.
    Iranian Journal of Medical Hypotheses and Ideas 07/2013; 7(2):54–58.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Graphical abstract Figure optionsDownload full-size imageDownload as PowerPoint slide
    Iranian Journal of Medical Hypotheses and Ideas 01/2014;

Full-text (2 Sources)

Download
19 Downloads
Available from
May 22, 2014

Tabinda Hasan